Week in Review: Mevion Medical of Boston Closes $150 Million Financing from China Investors

Deals and Financings 

 Trials and Approvals

• Ascletis Pharma of Hangzhou reported approval for its lead drug, Ganovo® (danoprevir), an innovative treatment for hepatitis C;
• China approved its first PD-1 immunotherapy: Opdivo, a Bristol-Myers Squibb drug, is indicated as a second-line treatment for NSCLC;
• CStone Pharma of Suzhou has begun pivotal Phase II studies of its lead drug, a PD-L1 antibody, in two forms of lymphoma;
• Everest Medicines, a US-China startup that in-licenses drugs for China's market, filed an IND to start a Phase III clinical trial of its novel antibiotic, eravacycline.

Stock Symbols: (SHZ: 300326) (HK: 0656) (HK: 2269) (NSDQ: APTO; TSX: APS) (KOSDAQ: 083790) (SHA: 603259) (NYSE: BMY)

Share this with colleagues:

More From BioPortfolio on "Week in Review: Mevion Medical of Boston Closes $150 Million Financing from China Investors"